Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

A new study employing novel single-cell multimodal data revealed key insights into the tumor microenvironment predictive of NSCLC treatment response.

Immunotherapies are undoubtedly transforming the landscape of cancer treatment worldwide. By harnessing the body's immune ...

The presentation will feature the design and objectives of the Phase 1 study, which marks the first clinical application of ...

Immutep’s efti with radiotherapy and pembrolizumab meets primary endpoint in phase II trials for soft tissue sarcoma ...

Highly pathogenic avian influenza viruses like H5N1, H5N6, and H7N9 pose an evolving global threat due to their capacity to ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

Inhalable nanovaccines offer needle-free, mucosal immunity against respiratory diseases like COVID-19, influenza, and TB. Explore delivery mechanisms, key technologies, and future breakthroughs.

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting for patients with resectable soft tissue sarcomaDetailed results are planne ...

DelveInsight’s Natural Killer (NK)-Cell Lymphoma Pipeline report depicts a robust space with 100+ active players working to develop 140+ pipeline therapies for Natural Killer (NK)-Cell Lymphoma ...